Indication · with advanced or metastatic solid tumors

with advanced or metastatic solid tumors FDA approvals, PDUFA dates and pipeline.

Updated Snapshot 20261116T222116ZBuilt

We track 1 with advanced or metastatic solid tumors drug. No FDA approvals recorded yet.

Drugs

DrugSponsorModalityDesignations
atebimetinibIMRXsmall_moleculeFast Track, Orphan Drug

Upcoming catalysts

No events in this view.

Past catalysts and decisions

DateDrugCompanyEventIndicationStatusSource
Sep 2022Month disclosedatebimetinibIMRXTrial startwith advanced or metastatic solid tumorsCompletedSEC Form 10-Q

All indications · Approval rates by indication

Not submitted to search engines: Needs 2 drugs and 3 sourced events; has 1 and 1.

Questions

What with advanced or metastatic solid tumors drugs have upcoming PDUFA dates?

None disclosed.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.